Search Reset All Therapy AreasAge-Related Macular DegenerationAsthmaBreast CancerCardiovascularHodgkin’s LymphomaMalignant MelanomaMigraineMultiple MyelomaMultiple SclerosisNeurologyNon-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaOncologyOphthalmologyOsteoarthritic PainOsteoarthritisParkinson's DiseasePsoriasisPsoriatic ArthritisRheumatoid ArthritisUlcerative Colitis All ProductsBiosimilarsChina In-DepthCurrent TreatmentEmerging TherapiesEpidemiologyProductSpecial Topics / OtherTreatment Algorithms: Claims Data AnalysisUnmet Need All GeographyChileUS All Years20222020201920182017201620152014 Previous1...345 October 14, 2015 Breast Cancer | Emerging Therapies | Ibrance (palbociclib) | US | Wave 2 | 2015 August 13, 2015 Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 3 | 2015 June 17, 2015 Psoriasis | Emerging Therapies | Cosentyx (secukinumab) | US | Wave 1 May 20, 2015 Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 2 | 2015 May 15, 2015 Breast Cancer | Emerging Therapies | Ibrance (palbociclib) | US | Wave 1 | 2015 May 15, 2015 Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 2 | 2015 April 1, 2015 Osteoarthritic Pain – As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? | Decision Base | US/EU5 | 2015 March 25, 2015 Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 1 | 2015 December 19, 2014 Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 1 | 2014 Previous1...345